PFS Benefit Observed With Tucatinib Plus T-DM1 in Previously Treated HER2+ Metastatic Breast Cancer

The addition of tucatinib to ado-trastuzumab emtansine (T-DM1) significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer, including those with brain metastases.

Related Keywords

Texas ,United States ,Phoenix ,Arizona ,San Antonio ,Genentech Roche ,Astra Zeneca ,Eli Lilly ,Pfizer ,Alliance Foundation ,Novartis ,Greenwich Life Sciences Inc ,Phoenix Molecular Designs Ltd ,Antonio Breast Cancer Symposium ,Phoenix Molecular Designs ,Quantum Leap ,Tucatinib Plust Dm1 ,Tucatinib ,T Dm1 ,Tukysa ,Ado Trastuzumab Emtansine ,Kadcyla ,Phase 3 Her2climb 02 Trial ,Sabcs ,San Antonio Breast Cancer Symposium ,Saraa Hurvitz ,D ,Fred Hutchinson Cancer Center ,